biosimilars
The latest news about biosimilars: headlines, AI summaries and the full story from every source.
- Kamada Ltd. Reports Strong Q3 2026 Results and Raises Full-Year Guidance
- Teva Pharmaceutical Acquires U.S. Commercialization Rights for Samsung Bioepis Biosimilars
- Teva and Samsung Bioepis Partner on Up to Six Biosimilars
- Teva Receives FDA Approval for Biosimilar Version of Amgen's Xgeva
- Sandoz Receives Canadian Approval for Generic Ozempic and Biosimilar Licensing Deal
- U.S. Faces Potential $189 Billion Loss in Healthcare Savings Due to Biosimilar Void
- Johnson & Johnson Aims for Double-Digit Growth Amid STELARA Biosimilar Competition
- Teva Pharmaceuticals Accelerates Growth Strategy with Branded Drugs and Biosimilars
- AbbVie's Reduced Commentary on Humira Amid Biosimilar Competition
- Sandoz Outlines Ambitious Biosimilar Growth Strategy with Bio100 Roadmap
- Amneal Pharmaceuticals Reports Q2 2026 Earnings with Strategic Shifts and Guidance Update
- Study Suggests States Could Save Up to $1.8 Billion Annually by Using Lower-Cost Biosimilars
- Teva Reports Positive Austedo Data and Expands Biosimilars Portfolio
- Alvotech Shares Rise After FDA Accepts Entyvio Biosimilar Application for Review
- Alvotech Shares Rise as FDA Accepts BLA for Entyvio Biosimilar
- Alvotech Resubmits U.S. Applications for Biosimilars Targeting J&J's Simponi and Regeneron's Eylea
- Alvotech Provides Q4 2025 Earnings Update
- Amneal Reports Q2 2025 Earnings with Revenue Growth
- Option Care Health Reports Q1 Results and Lowers Revenue Guidance
- Amneal Pharmaceuticals Announces Q1 2026 Earnings and Acquisition of Kashiv BioSciences
- AbbVie Exceeds First-Quarter 2026 Earnings and Raises Full-Year Forecast
- AbbVie Exceeds Quarterly Revenue and Profit Expectations as Newer Immunology Drugs Offset Humira Decline
- Amneal Pharmaceuticals Q1 2026 Earnings Call Summary
- West Pharmaceutical Services Reports Strong Q1 2026 Earnings with Revenue Growth and Guidance Update